Exelixis (NASDAQ:EXEL) EVP Patrick Haley Sells 67,814 Shares

Exelixis, Inc. (NASDAQ:EXEL) EVP Patrick Haley sold 67,814 shares of Exelixis stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $43.52, for a total transaction of $2,951,265.28. Following the sale, the executive vice president owned 381,908 shares in the company, valued at approximately $16,620,636.16. This represents a 15.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Exelixis Trading Up 0.9%

EXEL stock traded up $0.39 during trading on Wednesday, hitting $44.47. The company had a trading volume of 3,267,412 shares, compared to its average volume of 2,563,792. The business has a 50 day moving average of $43.77 and a 200 day moving average of $41.13. The firm has a market capitalization of $11.55 billion, a price-to-earnings ratio of 16.05, a P/E/G ratio of 0.99 and a beta of 0.42. Exelixis, Inc. has a fifty-two week low of $32.38 and a fifty-two week high of $49.62.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.20. The company had revenue of $598.66 million for the quarter, compared to the consensus estimate of $609.17 million. Exelixis had a net margin of 33.73% and a return on equity of 36.29%. Exelixis’s revenue was up 5.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.55 EPS. As a group, equities analysts predict that Exelixis, Inc. will post 2.04 EPS for the current year.

Institutional Trading of Exelixis

A number of hedge funds have recently bought and sold shares of EXEL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Exelixis by 81.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock valued at $1,592,000 after purchasing an additional 19,407 shares during the period. Goldman Sachs Group Inc. increased its stake in Exelixis by 4.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock valued at $54,153,000 after buying an additional 68,133 shares during the period. Focus Partners Wealth lifted its position in Exelixis by 83.4% in the 1st quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock worth $1,420,000 after buying an additional 17,483 shares in the last quarter. Geneos Wealth Management Inc. boosted its stake in shares of Exelixis by 134.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 944 shares during the period. Finally, Sivia Capital Partners LLC grew its holdings in shares of Exelixis by 23.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock valued at $633,000 after acquiring an additional 2,764 shares in the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

EXEL has been the subject of a number of research reports. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Exelixis in a research note on Thursday, January 22nd. Oppenheimer reaffirmed a “market perform” rating and set a $36.00 target price on shares of Exelixis in a research note on Wednesday, November 5th. UBS Group set a $41.00 price target on shares of Exelixis in a research report on Monday, January 5th. Stifel Nicolaus upped their price target on shares of Exelixis from $43.00 to $44.00 and gave the company a “hold” rating in a report on Wednesday, February 11th. Finally, TD Cowen restated a “buy” rating on shares of Exelixis in a research report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $47.11.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.